UBS keeps JPY 15,000 target for Otsuka Holdings stock
Published on 10/20/2026 at 22:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUBS target and reporting date
- UBS kept a JPY 15,000 target for Otsuka Holdings on October 6, 2026.
- Fiscal 2026 revenue guidance rose from JPY 2.520 trillion to JPY 2.725 trillion.
- Otsuka Holdings stock costs EUR 70.25 at Lang & Schwarz on October 20, 2026 at 10:19 p.m. CEST.
- Otsuka Holdings is scheduled to report its third-quarter results on October 30, 2026.
UBS kept its Buy rating and a JPY 15,000 12-month target for Otsuka Holdings on October 6, 2026, according to IT Boltwise. Against the Tokyo price of JPY 12,360 on October 20, 2026, that target stands 21.36 percent higher. Otsuka Holdings stock was trading at EUR 70.25 at Lang & Schwarz on October 20, 2026 at 10:19 p.m. CEST.
Guidance rises to JPY 2.725 trillion
The more immediate operating signal is Otsuka's revised fiscal 2026 outlook. The company lifted revenue guidance from JPY 2.520 trillion to JPY 2.725 trillion, an increase of 8.13 percent, while operating profit guidance rose from JPY 360.0 billion to JPY 469.0 billion.
JPX Market Explorer reported the revision on October 19, 2026, citing stronger pharmaceutical revenue and delayed generic competition for JYNARQUE and ABILIFY MAINTENA.
What does the JPY 15,000 target imply?
The target requires a 21.36 percent rise from the JPY 12,360 Tokyo price. UBS also linked its view to Otsuka's uRDN renal-denervation treatment, for which reimbursement status was upgraded to Class I, with potential revenue of JPY 100.0 billion to JPY 200.0 billion after reimbursement begins, according to Futunn on October 2, 2026.
Valuation and October 30 results
Otsuka Holdings had a price-to-earnings ratio of 16.09 and a market capitalization of JPY 6.5 trillion as of October 20, 2026. Takeda Pharmaceutical traded at a price-to-earnings ratio of 56.25 with a JPY 10.0 trillion market capitalization, while Chugai Pharmaceutical had a ratio of 22.45 and a JPY 10.6 trillion market capitalization.
Otsuka is scheduled to report results for the quarter ended September 30, 2026, on October 30, 2026. Estimates cited by Finanzen.ch include revenue of JPY 699.85 billion, up 9.70 percent from JPY 637.98 billion a year earlier.
Otsuka stock keeps its valuation frame
The combination of higher fiscal guidance and a near-term reporting date gives the JPY 15,000 target a clear test. The next reported quarter will show whether pharmaceutical growth is translating into the revised annual profit outlook.
The further course of trading is shown by the continuously updated real-time quote of Otsuka Holdings stock.
Otsuka Holdings market facts
- Company: Otsuka Holdings Co., Ltd.
- ISIN: JP3188220002
- Ticker: 4578
- Primary exchange: Tokyo Stock Exchange
- Price Lang & Schwarz (as of October 20, 2026, 10:19 p.m. CEST): EUR 70.25
- Market capitalization: JPY 6.5 trillion (as of October 20, 2026)
- 52-week range: JPY 8,018.00-12,795.00 (as of October 20, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: Nikkei 225
- Next earnings date: October 30, 2026
Market context: Market report Nikkei 225.
